June 25, 2020—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has announced the addition of Mike Nicholson, Ph.D. to its leadership team as Vice President, Operations. In this role, Dr. Nicholson will oversee bioanalytical operations and scientific team development across BioAgilytix’s laboratories in both the USA and Europe, with particular focus leading the organization’s Gene and Cell Therapy bioanalytical services.
Prior to joining BioAgilytix, Dr. Nicholson spent nearly 13 years at Precision BioSciences where he held several leadership roles including Executive Director of Scientific Operations, Vice President of R&D, and Senior Vice President of Research. Dr. Nicholson played a key role in developing Precision Biosciences’ novel gene editing platform and led research teams focused on allogeneic CAR-T therapies and gene editing-based gene therapies. During his tenure there he also led Human Resources for over 2 years as Chief People Officer. Dr. Nicholson earned his Ph.D. in molecular biology and genetics from the Johns Hopkins School of Medicine and carried out postdoctoral research at the University of North Carolina, Chapel Hill.
“Mike’s background is unique in that he brings deep expertise in gene editing, cell therapy, and gene therapy development along with diverse biotech executive experience in positions ranging from SVP of Research to Chief People Officer,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “His combination of scientific knowledge and proven leadership will be invaluable to our organization, particularly as we continue to build a world-class Gene and Cell Therapy bioanalytical offering for our customers – many of whom are now focusing on these exciting modalities to address previously untenable diseases. He will ensure our team is equipped to deliver high-quality bioanalytical solutions that successfully progress the development of novel and complex therapies.”
“BioAgilytix’s impressive reputation and track record are built on a foundation of ‘science and service first’, and I am thrilled to now be a part of this leading team,” said Dr. Nicholson. “I look forward to learning more from our customers what their current and future large molecule testing opportunities and challenges entail, so we can continue to align and grow our talent and resources with their needs as a world-class provider and their go-to partner.”
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area, the Cambridge area of Massachusetts, and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.). BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.